Get the Stockscreener App
0.0718
1.64%
-0.0012
After Hours:
.07
-0.0018
-2.51%
Petros Pharmaceuticals Inc stock is traded at $0.0718, with a volume of 7.79M.
It is down -1.64% in the last 24 hours and down -54.47% over the past month.
Petros Pharmaceuticals Inc is a men's health pharmaceutical company. It focuses on therapeutics that promote medication adherence, tolerability, and preservation of male organic function. The company's operating segment includes Prescription Medications and Medical Devices. It generates maximum revenue from the Medical Devices segment. The Prescription Medications segment consists of operations related to vacuum erection devices, which are sold domestically and internationally.
See More
Previous Close:
$0.073
Open:
$0.0624
24h Volume:
7.79M
Relative Volume:
1.08
Market Cap:
$1.81M
Revenue:
$4.02M
Net Income/Loss:
$-4.73M
P/E Ratio:
-0.0171
EPS:
-4.21
Net Cash Flow:
$-5.85M
1W Performance:
-21.87%
1M Performance:
-54.47%
6M Performance:
-80.86%
1Y Performance:
-95.05%
1-Day Range:
$0.0612
$0.0726
1-Week Range:
$0.0612
$0.0902
52-Week Range:
$0.0612
$1.59
Petros Pharmaceuticals Inc Stock (PTPI) Company Profile
Name
Petros Pharmaceuticals Inc
Sector
Phone
973-242-0005
Address
1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK
Compare PTPI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PTPI
Petros Pharmaceuticals Inc
|
0.0718 | 1.81M | 4.02M | -4.73M | -5.85M | -4.21 |
|
ZTS
Zoetis Inc
|
163.75 | 73.33B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.13 | 47.80B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.37 | 46.89B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.29 | 18.67B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
131.53 | 13.99B | 612.78M | -86.37M | -62.91M | -0.87 |
Petros Pharmaceuticals Inc Stock (PTPI) Latest News
PTPI stock plunges to 52-week low of $0.07 amid market challenges By Investing.com - Investing.com South Africa
PTPI stock plunges to 52-week low of $0.07 amid market challenges - Investing.com Australia
PTPI’s price-to-free cash flow ratio: How it affects investment decisions - US Post News
Internationally Published, Head-to-Head Data From India of Petros Pharmaceuticals' STENDRA(R) (Avanafil) Tablets Reported Improvement in Erectile Function Compared to Sildenafil and Baseline After 12 Weeks of Therapy - ACCESS Newswire
Petros Pharmaceuticals Reports Record Revenue and Gross Profit During Second Quarter 2022 - ACCESS Newswire
New FDA-Approved Labeling for Petros Pharmaceuticals’ STENDRA (avanafil) Now Includes Efficacy Data Regarding Use in Men Who Have Undergone Radical Prostatectomy - ACCESS Newswire
Petros Pharmaceuticals stock hits 52-week low at $0.1 By Investing.com - Investing.com South Africa
Petros Pharmaceuticals stock hits 52-week low at $0.1 - Investing.com
Artificial Intelligence (AI) News Live Feed - StockTitan
Petros reports success in AI-assisted Rx-to-OTC study - Investing.com India
Petros reports success in AI-assisted Rx-to-OTC study By Investing.com - Investing.com South Africa
Petros Pharmaceuticals' Proprietary Technology Demonstrates Positive Data in Pivotal Study - ACCESS Newswire
Can Petros Pharmaceuticals' AI-Powered Platform Revolutionize the $38B Self-Care Market? - StockTitan
PTPI Page Not Found - Benzinga
Petros Pharmaceuticals announces pricing of $9.6 million public offering - MSN
Form 424B4 Petros Pharmaceuticals, - StreetInsider.com
PTPI stock plunges to 52-week low of $0.15 amid market challenges - Investing.com India
Crude Oil Gains 1.5%; Fluor Shares Plunge Following Downbeat Earnings - Benzinga
Watsco, Septerna, Nike - TradingView
Petros Pharmaceuticals Prices $9.6 Million Public Offering of Shares, Warrants -February 18, 2025 at 09:52 am EST - Marketscreener.com
US Stocks Mixed; NY State Business Activity Rises In February - Benzinga India
Petros Pharmaceuticals sets public offering at $0.24 per share - Investing.com
Petros Pharmaceuticals prices 40M shares at 24c in public offering - TipRanks
Petros Pharmaceuticals Announces Pricing of $9.6 Million Public Offering of Common Stock and Warrants - ACCESS Newswire
Major Capital Raise: Petros Pharmaceuticals Locks $9.6M Financing DealStrategic Move or Dilution Risk? - StockTitan
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Petros Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference - ACCESS Newswire
Best Penny Stocks for Today (Charts Updated Daily) - Benzinga
Petros Pharmaceuticals Enters into AI Licensing Agreement with Leading Multi-Billion-Dollar Software Provider - ACCESS Newswire
Petros Pharmaceuticals (NASDAQ:PTPI) Trading 5.2% Higher – Still a Buy? - Defense World
Erectile Dysfunction Treatment Drugs Market to Hit USD 5.97 Billion by 2032, Growing at a 6.84% CAGR - EIN News
Analytical Lens: Exploring Perella Weinberg Partners (PWP)’s Financial Story Through Ratios - The Dwinnex
Balance Sheet Breakdown: Petros Pharmaceuticals Inc (PTPI)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Petros Pharmaceuticals Inc’s (PTPI) Stock: A Week-by-Week Analysis - The News Heater
Petros Pharmaceuticals Announces Capital Raise of $15 Million - accessnewswire.com
Petros Pharmaceuticals Receives Positive Response from FDA Following Recent Demonstration of Technology Component in Pursuit of OTC Status for STENDRA(R) (avanafil) - ACCESS Newswire
Petros Pharmaceuticals Strategically Positioned to Benefit as Technology Leader from Newly Approved FDA OTC Final Rules - accessnewswire.com
Petros Pharmaceuticals Successfully Completes Important Study in Effort to Make STENDRA(R) (avanafil) the First Erectile Dysfunction Medication to Achieve OTC Status - ACCESS Newswire
Johnson & Johnson posts Q4 beat as drug sales offset MedTech weakness - MSN
Petros Pharmaceuticals modifies terms with investors By Investing.com - Investing.com India
Harmony Biosciences chief commercial officer sells shares worth $1.15m - MSN
Petros Pharmaceuticals Successfully Launches AI Tool In Collaboration with Multi-Billion-Dollar Software Provider - ACCESS Newswire
Microvast files for $250M mixed securities shelf offering - MSN
Proprietary Technology Addressing the Rx-to-OTC Switch Self-Care Market Valued at over $38 Billion annually - ACCESS Newswire
Petros Pharmaceuticals Partners with Blockbuster Cholesterol Drug(1) Crestor’s (rosuvastatin) OTC Switch Technology Provider - ACCESS Newswire
Janbelco BV trims stake in Thalassa Holdings - MSN
Immedica to buy Marinus Pharmaceuticals for $151m - MSN
XORTX Therapeutics Announces Auditor Transition - MSN
Apellis Pharmaceuticals executive sells $36,998 in stock - MSN
Amneal gets FDA approval for generic Byetta, resubmits DHE NDA - MSN
Pharming Group appoints former Novartis USA President Fabrice Chouraqui as New CEO - MSN
Petros Pharmaceuticals Inc Stock (PTPI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.19%
0.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):